Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 14, Issue 10, Pages 882-892
Publisher
Wiley
Online
2012-03-15
DOI
10.1111/j.1463-1326.2012.01595.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control
- (2013) Helena Rodbard et al. Endocrine Practice
- Weight-Related Quality of Life, Health Utility, Psychological Well-Being, and Satisfaction With Exenatide Once Weekly Compared With Sitagliptin or Pioglitazone After 26 Weeks of Treatment
- (2011) J. H. Best et al. DIABETES CARE
- An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future
- (2011) S. Madsbad et al. DIABETES OBESITY & METABOLISM
- Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study
- (2011) W. E. Schmidt et al. DIABETIC MEDICINE
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
- (2010) J. B. Buse et al. DIABETES CARE
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
- (2010) B. W. Bode et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- DPP-4 inhibitors: What may be the clinical differentiators?
- (2010) John Gerich DIABETES RESEARCH AND CLINICAL PRACTICE
- Liraglutide: effects beyond glycaemic control in diabetes treatment
- (2010) J. B. McGill INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
- (2010) Richard E Pratley et al. LANCET
- Relationship Between Obesity and Diabetes in a US Adult Population: Findings from the National Health and Nutrition Examination Survey, 1999–2006
- (2010) Ninh T. Nguyen et al. OBESITY SURGERY
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
- (2010) Kjeld Hermansen et al. Primary Care Diabetes
- A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes
- (2010) Michael Polster et al. JOURNAL OF MEDICAL ECONOMICS
- Psychometric properties and responsiveness of the Turkish version of the Diabetes Treatment Satisfaction Questionnaire (s) on a sample of diabetics of three consecutive monitoring periods
- (2009) Bilgin Özmen et al. ACTA DIABETOLOGICA
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
- (2009) Sten Madsbad BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
- (2009) David J Grieve et al. BRITISH JOURNAL OF PHARMACOLOGY
- Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
- (2009) J. A. DAVIDSON CLEVELAND CLINIC JOURNAL OF MEDICINE
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
- (2009) M. H. Noyan-Ashraf et al. DIABETES
- Barriers to Insulin Injection Therapy
- (2009) Richard R. Rubin et al. DIABETES EDUCATOR
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain
- (2009) E. Marrett et al. DIABETES OBESITY & METABOLISM
- Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
- (2009) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life
- (2009) Michael F. Pollack et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents
- (2009) A. B. Hauber et al. DIABETIC MEDICINE
- Psychometric validation and use of a novel diabetes in-patient treatment satisfaction questionnaire
- (2009) M. J. Sampson et al. DIABETIC MEDICINE
- Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
- (2009) J. H. Best et al. DIABETIC MEDICINE
- Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes
- (2009) J. Speight et al. DIABETIC MEDICINE
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus
- (2009) F. Xavier Pi-Sunyer POSTGRADUATE MEDICINE
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial
- (2008) Reinhard G Bretzel et al. LANCET
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart
- (2007) David P. Sonne et al. REGULATORY PEPTIDES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search